Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40

Benzinga · 2d ago
Morgan Stanley analyst Thibault Boutherin downgrades Novo Nordisk (NYSE:NVO) from Equal-Weight to Underweight and maintains the price target from $40 to $40.